CyberKnife SBRT plus lenvatinib and tislelizumab versus doublet systemic therapy for hepatocellular carcinoma with macrovascular invasion: A real-world IPTW-adjusted study
Clinical and Translational Radiation Oncology · 2027-01 · 62 · 101290
DOI: 10.1016/j.ctro.2026.101290 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Radiation Oncology, 2027-01. Verfasst von Sujing Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Hospital of Hebei Medical University, No. 89 Donggang Road, Yuhua District, Shijiazhuang 050031, China. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background & purpose: Macrovascular invasion (MVI) in hepatocellular carcinoma (HCC) confers extremely poor prognosis. While lenvatinib plus tislelizumab is an active targeted-immunotherapy regimen, local control of tumor thrombus remains suboptimal. Stereotactic body radiotherapy (SBRT) delivered via CyberKnife offers highly conformal local treatment and may have immunomodulatory effects. We evaluated whether adding CyberKnife SBRT to doublet systemic therapy was associated with improved outcomes in HCC with MVI. Materials & methods: This real-world retrospective study included 116 HCC patients with MVI (Triple group: CyberKnife SBRT + lenvatinib + tislelizumab, n = 50; Doublet group: lenvatinib + tislelizumab, n = 66) - selected from a screened pool of 215 patients between June 2021 and June 2024. Stabilized inverse probability of treatment weighting (IPTW), with the propensity score derived from a multivariable logistic regression including nine baseline covariates and, as additional sensitivity analyses, an expanded 18-covariate model and a gradient-boosted-machine propensity score, balanced the measured baseline covariates (all standardized mean differences
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, The First Hospital of Hebei Medical University, No. 89 Donggang Road, Yuhua District, Shijiazhuang 050031, China.
- Department of Oncology, Hebei Cangzhou People's Hospital, Huanghe West Road, Yunhe District, Cangzhou 061001, China.
Zitieren
APA
Zhang, S., Shen, X., Wang, W., Zhang, M., Wang, S., Hao, H., & Zhao, Y. (2027). CyberKnife SBRT plus lenvatinib and tislelizumab versus doublet systemic therapy for hepatocellular carcinoma with macrovascular invasion: A real-world IPTW-adjusted study. Clinical and Translational Radiation Oncology, 62, 101290. https://doi.org/10.1016/j.ctro.2026.101290
Vancouver
Zhang S, Shen X, Wang W, Zhang M, Wang S, Hao H, et al. CyberKnife SBRT plus lenvatinib and tislelizumab versus doublet systemic therapy for hepatocellular carcinoma with macrovascular invasion: A real-world IPTW-adjusted study. Clinical and Translational Radiation Oncology. 2027;62:101290. doi:10.1016/j.ctro.2026.101290
BibTeX
@article{Zhang2027,
author = {Zhang, Sujing and Shen, Xiaoqian and Wang, Wei and Zhang, Miaomiao and Wang, Suming and Hao, Hui and Zhao, Yingchun},
title = {CyberKnife SBRT plus lenvatinib and tislelizumab versus doublet systemic therapy for hepatocellular carcinoma with macrovascular invasion: A real-world IPTW-adjusted study},
journal = {Clinical and Translational Radiation Oncology},
year = {2027},
volume = {62},
pages = {101290},
doi = {10.1016/j.ctro.2026.101290}
}
EUVIMED